Biogen Sets A High R&D Bar With A Pipeline That Extends Well Beyond MS
Executive Summary
The company has recruited top talent and is studying some of the most challenging areas within pharma, including neurodegenerative and rare diseases, but the high-risk, high-reward nature of the pipeline has spooked some investors.
You may also be interested in...
Scangos Leaves Biogen Transformed And Transitioning
CEO George Scangos built Biogen into an innovative biotech, but his departure, coming as the company dusts itself off after a fall from glory, increased speculation Biogen could become a takeout target.
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.